New Treatment Methods Discussed at World Conference on Lung Cancer
Highlighting the new-generation cancer drugs and international partnerships introduced at the congress in Seoul, the barriers patients face in accessing these treatments were emphasized.
Prof. Dr. Mustafa Özdoğan evaluated the prominent new cancer drugs, drug development partnerships between the US and China, and the issues patients face in accessing treatment at the World Conference on Lung Cancer held in Seoul.
Congress Impressions and Global Collaborations
Prof. Dr. Mustafa Özdoğan shared developments from the World Conference on Lung Cancer held in Seoul from September 12-15. It drew attention that the rights to cancer drug molecules developed in China were acquired by American companies through multi-billion dollar agreements.
International Competition and Scientific Discoveries
Partnerships in biotechnology and drug development between China and the US clearly demonstrated that scientific discoveries are becoming globalized beyond the competition between the two countries.
Prominent New-Generation Drugs
It was stated that ivonescimab, a dual-target antibody that stood out at the congress, positively affected median survival compared to pembrolizumab in non-small cell lung cancer.
Other Promising Treatments
The meeting also addressed new-generation treatment options such as tarlatamab and an antibody-drug conjugate named tambotatug pelitecan, which are being tested in the treatment of small cell lung cancer.
Patients' Treatment Access Problem
While it was pointed out that geographical boundaries are being crossed in drug development, the issues patients experience in accessing these innovative treatments due to price and reimbursement walls were emphasized as the primary issue.